Formycon AG (FYB) - Total Liabilities

Latest as of December 2025: €340.39 Million EUR ≈ $397.95 Million USD

Based on the latest financial reports, Formycon AG (FYB) has total liabilities worth €340.39 Million EUR (≈ $397.95 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Formycon AG strategic investment ratio to see how much of total assets are deployed in long-term investments.

Formycon AG - Total Liabilities Trend (2009–2025)

This chart illustrates how Formycon AG's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Formycon AG.

Formycon AG Competitors by Total Liabilities

The table below lists competitors of Formycon AG ranked by their total liabilities.

Company Country Total Liabilities
Marie Brizard Wine & Spirits
PA:MBWS
France €65.04 Million
Shanghai Challenge Textile Co Ltd
SHE:002486
China CN¥210.33 Million
Zhejiang Tuna Environmental Science & Technology Co Ltd
SHG:603177
China CN¥1.52 Billion
Jiangsu Xinri E-Vehicle Co Ltd
SHG:603787
China CN¥2.43 Billion
BP p.l.c
LSE:BP-A
UK GBX204.53 Billion
JSL S.A
SA:JSLG3
Brazil R$10.86 Billion
Wildcat Resources Ltd
AU:WC8
Australia AU$3.34 Million
Nanjing Chixia Development Co Ltd
SHG:600533
China CN¥14.53 Billion

Liability Composition Analysis (2009–2025)

This chart breaks down Formycon AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Formycon AG to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 2.33 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.85 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Formycon AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Formycon AG (2009–2025)

The table below shows the annual total liabilities of Formycon AG from 2009 to 2025.

Year Total Liabilities Change
2025-12-31 €340.39 Million
≈ $397.95 Million
+9.85%
2024-12-31 €309.87 Million
≈ $362.27 Million
-20.06%
2023-12-31 €387.61 Million
≈ $453.16 Million
-22.03%
2022-12-31 €497.12 Million
≈ $581.18 Million
+3253.46%
2021-12-31 €14.82 Million
≈ $17.33 Million
+96.00%
2020-12-31 €7.56 Million
≈ $8.84 Million
+41.51%
2019-12-31 €5.34 Million
≈ $6.25 Million
-16.28%
2018-12-31 €6.38 Million
≈ $7.46 Million
+20.82%
2017-12-31 €5.28 Million
≈ $6.18 Million
+23.03%
2016-12-31 €4.29 Million
≈ $5.02 Million
+88.68%
2015-12-31 €2.28 Million
≈ $2.66 Million
-30.28%
2014-12-31 €3.26 Million
≈ $3.82 Million
+2.22%
2013-12-31 €3.19 Million
≈ $3.73 Million
-5.48%
2012-12-31 €3.38 Million
≈ $3.95 Million
+639.50%
2011-12-31 €457.00K
≈ $534.28K
+118.40%
2010-12-31 €209.25K
≈ $244.64K
+243.03%
2009-12-31 €61.00K
≈ $71.32K
--

About Formycon AG

XETRA:FYB Germany Biotechnology
Market Cap
$404.97 Million
€346.39 Million EUR
Market Cap Rank
#14365 Global
#1441 in Germany
Share Price
€19.60
Change (1 day)
-1.01%
52-Week Range
€16.82 - €26.10
All Time High
€92.50
About

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more